Apicidin is a potent histone deacetylase inhibitor exhibiting broad-spectrum antiprotozoal, antiproliferative, and antiangiogenic activities. This study was conducted to calculate the intrinsic hepatic clearance of apicidin in mouse, rat, and human. The microsomal stability was determined in pooled microsomes of mouse, rat, and human. The V(max) and K(m) were 680.4 ng/min/mg protein and 10,544.1 ng/ml for mouse, 745.0 ng/min/mg protein and 24,306.0 ng/ml for rat, and 927.0 ng/min/mg protein and 62,906.0 ng/ml for human, respectively. The f(u,plasma) was extremely low, 0.369 +/- 0.034% for mouse, 0.376 +/- 0.059% rat, and 1.042 +/- 0.114% human. The unbound fraction of apicidin in microsomes (f(u,mic)) was also low, 1.731 +/- 0.237% for mouse, 0.767 +/- 0.048% for rat, and 5.751 +/- 1.575% for human. The hepatic intrinsic clearance calculated by Michaelis kinetics was further corrected by nonspecific binding to microsomal proteins. The corrected intrinsic clearance of apicidin was 1.9, 8.6, and 284.2 ml/min for mouse, rat, and human, respectively. The allometric correlation was improved when the hepatic intrinsic clearance was corrected by the nonspecific protein binding.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/15287390500181992 | DOI Listing |
Carbohydr Polym
March 2025
Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201210, China; Shenyang Pharmaceutical University, Shenyang 110016, China; University of Chinese Academy of Sciences, Beijing 100049, China. Electronic address:
Extracellular vesicles (EVs) are promising therapeutic carriers for their ideal nano-size and intrinsic biocompatibility, while rapid clearance and limited targeting ability are the major setbacks of EVs. With minimal absorption into the systemic circulation, inhalation for pulmonary disease therapy minimizes off-target toxicity to other organs and offers a safe and effective treatment for respiratory disorders. Herein, a nano-grid carrier made of boronated cyclodextrin framework (BCF) was prepared for pH/HO responsive release of EVs.
View Article and Find Full Text PDFDrug Des Devel Ther
January 2025
The First Affiliated Hospital of Wenzhou Medical University, Zhejiang, People's Republic of China.
Background: Givinostat, a potent histone deacetylase (HDAC) inhibitor, is promising for the treatment of relapsed leukemia and myeloma.
Purpose: This study aimed to develop and verify a quick assay for the measurement of givinostat concentration using ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) with eliglustat as the internal standard (IS), establishing a basic pharmacokinetic profile for its pre-clinical application and metabolic stability in vitro.
Methods: Sample preparation was performed via protein precipitation using acetonitrile.
Adv Mater
January 2025
State Key Laboratory of Chemical Resource Engineering, College of Chemistry, Beijing University of Chemical Technology, Beijing, 100029, China.
Urinalysis, as a non-invasive and efficient diagnostic method, is very important but faces great challenges due to the complex compositions of urine and limited naturally occurring biomarkers for diseases. Herein, by leveraging the intrinsic absence of endogenous fluorinated interference, a strategy with the enzymatically activated assembly of synthetic fluorinated peptide for cholestatic liver injury (CLI) diagnosis and treatment through F nuclear magnetic resonance (NMR) urinalysis and efficient drug retention is developed. Specifically, alkaline phosphatase (ALP), overexpressed in the liver of CLI mice, triggers the assembly of fluorinated peptide, thus, directing the traffic and dynamic distribution of the synthetic biomarkers after administration, whereas CLI mice display much slower clearance of peptides through urine as compared with healthy counterparts.
View Article and Find Full Text PDFJ Appl Stat
June 2024
Department of Computing and Mathematics, Manchester Metropolitan University, Manchester, UK.
Reproductive health significantly contributes to the overall well-being and social welfare of women. Within the spectrum of modern and traditional contraceptive methods in use, condoms have been strongly advocated by numerous HIV programs as a primary means of preventing HIV infection in Sri Lanka. Given the intrinsic relationship between contraceptive utilization and HIV awareness, our study aims to concurrently analyze the patterns of contraceptive usage and HIV knowledge, while accounting for their potential correlation.
View Article and Find Full Text PDFAAPS J
January 2025
Clinical Pharmacology Modeling and Simulation, Amgen, One Amgen Center Drive, Thousand Oaks, CA, 91320-0777, USA.
Sotorasib is a novel KRAS inhibitor that has shown robust efficacy, safety, and tolerability in patients with KRAS mutation. The objectives of the population pharmacokinetic (PK) analysis were to characterize sotorasib population PK in healthy subjects and patients with advanced solid tumors with KRAS mutation from 6 clinical studies, evaluate the effects of intrinsic and extrinsic factors on PK parameters, and perform simulations to further assess the impact of identified covariates on sotorasib exposures. A two-compartment disposition model with three transit compartments for absorption and time-dependent clearance and bioavailability well described sotorasib PK.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!